vTv Therapeutics (VTVT) Projected to Post Earnings on Wednesday

vTv Therapeutics (NASDAQ:VTVT) is expected to post its results before the market opens on Wednesday, May 13th. Analysts expect vTv Therapeutics to post earnings of $0.21 per share and revenue of $20.00 million for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.51. On average, analysts expect vTv Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

vTv Therapeutics Stock Performance

NASDAQ VTVT opened at $30.68 on Monday. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The stock’s fifty day moving average price is $36.42 and its 200-day moving average price is $33.66. The stock has a market cap of $120.88 million, a P/E ratio of -9.16 and a beta of 0.26.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Evercore assumed coverage on shares of vTv Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $44.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a report on Wednesday, March 11th. Roth Mkm started coverage on vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 price objective for the company. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Friday, March 27th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $53.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VTVT. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics in the 4th quarter worth $221,000. Geode Capital Management LLC raised its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the period. Finally, 683 Capital Management LLC bought a new stake in vTv Therapeutics during the fourth quarter valued at about $731,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.